JRoc16
$TNXP Scanned through companies last night. Many have the same charts we are seeing with TNXP as of late. Almost identical. Percentages vary due to float sizes, I'm seeing this all over the Market. We have a successful launch. Likely exponential sales through 2027 vs the linear growth we are seeing. Core issue is cashburn/dillution, once we secure a partnership we will eliminate/greatly reduce those concerns. The generic patent challenge is Bullish. We have a drug that others want. Sales continue to grow as stated last earnings call. Recently hired a team member specifically for partnerships. We're fully integrated and have proven we can launch a product successfully, so confident we are building a manufacturing facilty. The Lyme vaccine on deck could be a huge player, label expansion on an already great drug, approaching a 100M run rate in its 1st year of launch is a success. Seth will always keep 3-4 quarters of cash everyone knows this. I was anticipating 20M os shares this Q3.
17

:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_Getty_Images_2215332175_jpg_11a3fe7b09.webp)